Clinical Research Directory

Inclusion Criteria: * Age 18-75 years * Patients with suspected or confirmed solid tumors (e.g., prostate cancer, hepatocellular carcinoma, ovarian cancer, or endometrial cancer) * Patients scheduled to undergo tumor biopsy or surgical treatment within 2 months * ECOG performance status of 0 or 1 * Expected survival of at least 12 weeks * Adequate hematologic and organ function: * White blood cell count ≥ 4.0 × 10\^9/L or neutrophils ≥ 1.5 × 10\^9/L * Platelet count ≥ 100 × 10\^9/L * Hemoglobin ≥ 90 g/L * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * ALT/AST ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases) * Creatinine ≤ 1.5 × ULN * At least one measurable lesion according to RECIST 1.1 criteria * Ability to understand the study procedures and willingness to sign written informed consent Exclusion Criteria: * Severe hepatic or renal dysfunction * Inability to remain in a supine position for approximately 30 minutes during PET/CT scanning * Refusal or inability to participate in the clinical study * Claustrophobia or severe psychiatric disorders that would interfere with imaging procedures * Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study